Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marzia Defina

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
European Journal of Haematology|June 16, 2010
Low-dose rituximab in adult patients with primary immune thrombocytopeniaFrancesco Zaja, Nicola Vianelli, Stefano Volpetti, et al.
Cancer|April 21, 2012
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapyMarzia Defina, Micaela Ippoliti, Alessandro Gozzetti, et al.
Oncotarget|August 17, 2016
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patientsMonica Bocchia, Sara Galimberti, Lara Aprile, et al.
Pharmacogenomics and Personalized Medicine|May 2, 2022
Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib MonotherapyMonica Bocchia, Angelo Michele Carella, Antonino Mulè, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2013
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromesCarla Filì, Michele Malagola, Matilde Y Follo, et al.
Frontiers in Pharmacology|June 12, 2023
Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26<sup>+</sup> leukemia stem cellsPaola Pacelli, Adele Santoni, Anna Sicuranza, et al.
Haematologica|April 12, 2008
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpuraFrancesco Zaja, Marta Lisa Battista, Maria Teresa Pirrotta, et al.
Annals of Hematology|March 24, 2023
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL studyDavide Lazzarotto, Ilaria Tanasi, Antonella Vitale, et al.
Leukemia Research|September 26, 2022
Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all groupMarzia Defina, Davide Lazzarotto, Fabio Guolo, et al.
Haematologica|August 1, 2024
Ponatinib alone or with chemo-immunotherapy in heavily pre treated Philadelphia-like acute lymphoblastic leukemia: a CAMPUS ALL real-life studyFrancesca Kaiser, Monia Lunghi, Deborah Cardinali, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
European Journal of Haematology|June 16, 2010
Low-dose rituximab in adult patients with primary immune thrombocytopeniaFrancesco Zaja, Nicola Vianelli, Stefano Volpetti, et al.
Cancer|April 21, 2012
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapyMarzia Defina, Micaela Ippoliti, Alessandro Gozzetti, et al.
Oncotarget|August 17, 2016
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patientsMonica Bocchia, Sara Galimberti, Lara Aprile, et al.
Pharmacogenomics and Personalized Medicine|May 2, 2022
Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib MonotherapyMonica Bocchia, Angelo Michele Carella, Antonino Mulè, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2013
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromesCarla Filì, Michele Malagola, Matilde Y Follo, et al.
Frontiers in Pharmacology|June 12, 2023
Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26<sup>+</sup> leukemia stem cellsPaola Pacelli, Adele Santoni, Anna Sicuranza, et al.
Haematologica|April 12, 2008
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpuraFrancesco Zaja, Marta Lisa Battista, Maria Teresa Pirrotta, et al.
Annals of Hematology|March 24, 2023
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL studyDavide Lazzarotto, Ilaria Tanasi, Antonella Vitale, et al.
Leukemia Research|September 26, 2022
Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all groupMarzia Defina, Davide Lazzarotto, Fabio Guolo, et al.
Haematologica|August 1, 2024
Ponatinib alone or with chemo-immunotherapy in heavily pre treated Philadelphia-like acute lymphoblastic leukemia: a CAMPUS ALL real-life studyFrancesca Kaiser, Monia Lunghi, Deborah Cardinali, et al.
Pageof 7